Vericel (VCEL) Stock Price, News & Analysis

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VCEL shares.
View VCEL analyst ratings or view top-rated stocks.

6 equities research analysts have issued 1-year price targets for Vericel's shares. Their VCEL share price targets range from $39.00 to $55.00. On average, they anticipate the company's share price to reach $46.80 in the next year. This suggests that the stock has a possible downside of 3.2%.
View analysts price targets for VCEL or view top-rated stocks among Wall Street analysts.

Vericel's stock was trading at $35.61 at the beginning of 2024. Since then, VCEL stock has increased by 35.8% and is now trading at $48.35.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024.
View our VCEL earnings forecast.

Vericel Co. (NASDAQ:VCEL) released its quarterly earnings results on Wednesday, May, 8th. The biotechnology company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.11) by $0.03. The biotechnology company earned $51.28 million during the quarter, compared to analyst estimates of $49.07 million. Vericel had a trailing twelve-month return on equity of 0.21% and a net margin of 0.22%. The business's quarterly revenue was up 25.0% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.16) earnings per share.

ETFs with the largest weight of Vericel (NASDAQ:VCEL) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), WisdomTree BioRevolution Fund (WDNA), Invesco S&P SmallCap Health Care ETF (PSCH), ALPS Medical Breakthroughs ETF (SBIO), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), SPDR S&P Biotech ETF (XBI), Invesco S&P SmallCap 600 Pure Growth ETF (RZG) and Syntax Stratified SmallCap ETF (SSLY).

Vericel issued an update on its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $238.0 million-$242.0 million, compared to the consensus revenue estimate of $239.2 million.

6 employees have rated Vericel Chief Executive Officer Nick Colangelo on Glassdoor.com. Nick Colangelo has an approval rating of 49% among the company's employees. This puts Nick Colangelo in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Vericel investors own include Exelixis (EXEL), Novavax (NVAX), Hello Group (MOMO), Dynavax Technologies (DVAX), Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Verastem (VSTM), Amarin (AMRN) and NVIDIA (NVDA).

Vericel's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (7.06%), Conestoga Capital Advisors LLC (4.82%), BNP PARIBAS ASSET MANAGEMENT Holding S.A. (2.11%), William Blair Investment Management LLC (1.74%), Congress Asset Management Co. MA (1.73%) and Geneva Capital Management LLC (1.40%). Insiders that own company stock include Dominick Colangelo, Jonathan Mark Hopper, Jonathan Siegal, Michael Halpin, Paul K Wotton, Robert L Md Zerbe, Sean C Flynn and Steven C Gilman.
View institutional ownership trends.

Shares of VCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.